The Impact of Obesity Medications on Physical Function: What New Data Shows

Recent research indicates that obesity management medications may improve self-reported physical function in patients, while providing modest gains in objective measures of mobility. According to findings presented at the American Diabetes Association (ADA) 2026 Scientific Sessions in New Orleans, these treatments demonstrate positive effects on quality-of-life metrics without the negative impacts on physical performance that some had previously feared.

How Do Obesity Medications Affect Physical Function?

A systematic review and meta-analysis evaluated the effect of various obesity management medications on physical function. Researchers analyzed data from 30 randomized, controlled trials involving 25,088 participants. The study populations were predominantly female and non-Hispanic White, with mean ages ranging from 34.7 to 59.3 years. The medications studied included semaglutide, tirzepatide, liraglutide, naltrexone/bupropion, and phentermine/topiramate.

The results showed a statistically significant improvement in self-reported physical function. Using validated tools—specifically the Short Form-36 and the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) measures—the study found mean differences of 1.76 and 5.58, respectively (P < .01 for both). Regarding objective performance, three of the included studies utilized the 6-Minute Walk Test, which suggested modest gains compared to control groups.

What Are the Clinical Implications?

The study authors concluded that concerns regarding potential negative effects of newer weight-management drugs on physical function may not be warranted. As Alexandra Peary, a PhD student at Johns Hopkins University who presented the findings, noted, self-reported physical function showed modest improvement following treatment. This is significant given the complexity of obesity, which the World Health Organization (WHO) classifies as a chronic, relapsing disease influenced by genetics, neurobiology, and environmental factors.

It is important to note that this was an observational study, which cannot definitively demonstrate cause and effect. Trial durations across the analyzed studies spanned 20 to 72 weeks. While these medications are increasingly used as part of comprehensive weight management strategies, the Centers for Disease Control and Prevention (CDC) emphasizes that obesity is a complex, multifactorial condition influenced by health behaviors, stress, and underlying medical conditions.

Understanding Obesity and Treatment Goals

Obesity is defined by the WHO as having a body mass index (BMI) of 30 or higher for adults. Because obesity can affect multiple body systems and overall quality of life, clinical management often involves a combination of dietary changes, increased physical activity, and medical support, according to the Cleveland Clinic. As research continues to evolve, the focus remains on how pharmacological interventions can support not just weight reduction, but also the functional well-being of patients living with the disease.

Key Takeaways

• Improved Metrics: Patients reported better physical function on standardized quality-of-life scales following treatment with weight-management medications.
• Objective Gains: Limited data from the 6-Minute Walk Test suggests modest improvements in actual physical mobility.
• Safety Profile: The findings suggest that common fears regarding potential physical performance declines during treatment may not be supported by current clinical evidence.
• Study Scope: The meta-analysis covered 25,088 participants across 30 trials, highlighting the need for continued observation as these treatments become more common.